Impact Factor
3.15
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.95
822 total citations
h5-index
22
h5 depth signal
Cited share
64.0%
272 of 425
Total citations
822
Citation footprint
Metric signal
1.99
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
208
Germany
13
Canada
11
Brazil
7
Netherlands
7
Citing Fields of Research
Dermatology
1,045
Allergies
213
Musculoskeletal Disorders
123
Cosmetic Surgery
103
Oncology
99
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,355
Articles tracked across the journal lifetime
Indexed publication set
425
272 cited publications
Last 12 months
268
22.3 publications/month
Open access share
0.0%
0 OA publications in the last year
Leading citing country
United States
208 citing publications
Leading citing field
Dermatology
1,045 citing publications
Latest tracked publication
1 September 2026
10 recent records available
Coverage & Indexing History
v1n1, July 2002-
v1n1, July 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Dermatology
Broad Categories
Dermatology
MeSH Descriptors
Dermatologic Agents
Skin Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.36849/jdd.9957
Open DOI
Cicatricial Ectropion in the Setting of IL-13 Inhibition
Introduction: Interleukin (IL)-13 is a key mediator of type 2 inflammation and an important therapeutic target in atopic dermatitis (AD). Although IL-4/IL-13 and IL-13 inhibitors demonstrate favorable safety profiles, ocular adverse even...
02
DOI 10.36849/jdd.9880
Open DOI
Off-Label Uses of Nemolizumab: A Narrative Review
Background: Nemolizumab, a humanized monoclonal antibody targeting interleukin-31 receptor α (IL-31Rα), is approved for atopic dermatitis (AD) and prurigo nodularis (PN) in adults and pediatric patients 12 years and older, following phas...
03
DOI 10.36849/jdd.9852
Open DOI
Post-Inflammatory Hyperpigmentation in Skin of Color Patients With Atopic Dermatitis
Atopic dermatitis, pruritus, Fitzpatrick skin types, post-inflammatory hyperpigmentation, skin barrier dysfunction
04
DOI 10.36849/jdd.9771
Open DOI
Biopsy Type and Metastatic Recurrence in Melanoma: A Cohort Study
Background: Melanoma is a dynamic health problem caused by deteriorating melanocytes that generate aberrant melanin that gives color to the skin. It remains the leading cause of death from skin cancer. The incidence and mortality rates o...
05
DOI 10.36849/jdd.9756
Open DOI
Biologics and Small-Molecule Inhibitors for the Treatment of Nummular Eczema: A Systematic Review
Background: Nummular eczema (NE) is a chronic, pruritic dermatitis with substantial patient burden and no FDA-approved therapies. Emerging data suggest that biologics and small-molecule inhibitors may be promising therapeutic options for...
06
DOI 10.36849/jdd.9660
Open DOI
Nordic European Countries Atopic Dermatitis (NECAD) I: Importance of Concordance With Skincare for Atopic Dermatitis
Background: Atopic dermatitis (AD) is a chronic disease with a dysfunctional skin barrier, requiring continuous management to reduce symptoms and prevent flares. Topical treatment comprises the cornerstone of AD management. The paper’s o...
07
DOI 10.36849/jdd.9650
Open DOI
Differences in Atopic Dermatitis Comorbidity and Treatment Patterns by Race
Atopic dermatitis, comorbidities, treatment patterns, racial disparities, racial differences
08
DOI 10.36849/jdd.9619
Open DOI
Pulsed Dye Laser for Sensory Dysesthesias Associated With Chronic Radiation Dermatitis
Chronic radiation dermatitis (CRD) is a long-term complication of radiation therapy, typically manifesting as scarred atrophic plaques with telangiectasias. In some cases, patients report persistent sensory dysesthesias such as burning, ...
09
DOI 10.36849/jdd.9507
Open DOI
A Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis
Background: Seborrheic dermatitis (SD) is a chronic inflammatory skin condition driven by overactive sebaceous glands, Malassezia colonization, immune dysfunction, and epidermal barrier disruption. While topical corticosteroids and antif...
10
DOI 10.36849/jdd.946302
Open DOI
INDIVIDUAL ARTICLE: Ammonium Lactate in Clinical Practice: Optimizing Treatment of Xerotic and Hyperkeratotic Skin Conditions
Ammonium lactate is a well-established, time-tested dermatologic therapy with a substantial body of clinical evidence supporting its use in xerotic and hyperkeratotic skin conditions. Although its use in routine practice has evolved over...
Bibliographical & Catalog Notes
Title from cover.
Beginning with Nov. 4, 2010, includes a supplement entitled DermPearls.
Also issued online.